Overview

Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding

Status:
Terminated
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in the United States of the America (USA). The aim of this trial is to evaluate the effectiveness of activated recombinant human factor VII to mitigate experimentally-induced bleeding in healthy volunteers treated with clopidogrel (Plavix®).
Phase:
Phase 1
Details
Lead Sponsor:
Novo Nordisk A/S
Treatments:
Clopidogrel
Ticlopidine